GlassScriptPhysician profile
Stacy Y Oshry
NPI 1225038466
$6,174.09
in general payments reported to CMS, 2019-2025
50 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $239 · 2021: $1,085 · 2022: $929 · 2023: $870 · 2024: $1,025 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,116.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,277.26 | 2019-2025 | |
| Novo Nordisk INC | $1,038.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $593.02 | 2019-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $574.12 | 2019-2025 | |
| Astellas Pharma US INC | $306.69 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $303.09 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.85 | 2019-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $140.78 | 2021-2022 | |
| Lilly USA, LLC | $132.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amneal Pharmaceuticals LLC | $122.70 | 2021-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.50 | 2019-2021 | |
| Amarin Pharma, INC. | $103.38 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $86.86 | 2022 | |
| Sumitomo Pharma America, INC. | $86.47 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $82.54 | 2019-2025 | Lagevrio, Capvaxive, Gardasil |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Oshry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.